

Kahaani Zameen Par | Second Edition | Dr. Lal PathLabs Ltd.

On ground diagnosis

6th November 2017

BSE Code - 539524 | Scrip Name - LALPATHLAB | CMP - INR 826 | Market Capitalization ~6,883 crores



Investment Thesis	On-ground findings	View
<p>USP of Dr. Lal Pathlabs</p> <ul style="list-style-type: none"> ✓ Report Accuracy ✓ Doctor Referral 	<ul style="list-style-type: none"> ✓ More than 55% of the franchisee owners we spoke to said that <i>the report accuracy of Dr. Lal is very good. Dr. Lal Pathlabs reports are trusted by doctors.</i> <i>"Most doctors ask for Dr Lal Pathlabs report. All defence personnel at the time of recruitment have to go through medical screening test with Dr Lal's only" – South based franchisee owner</i> ✓ More than 20% of franchisee owners have mentioned that Dr. Lal has a very good doctor referral 	<p>Positive: This will help Dr. Lal PathLabs to grow</p>
<p>Competitive Pricing</p>	<ul style="list-style-type: none"> ✓ Thyrocare is the cheapest amongst the organized chains across regions (67% of responses) ✓ However the key competitor of Dr. Lal Pathlabs is SRL (88%) and Metropolis (75%). Few of them have mentioned that Dr. Lal is cheaper than SRL as well as has better quality report <i>"SRL is costly, Dr Lal Pathlab is cheaper and has a better quality report" - South based franchisee owner</i> 	<p>Neutral</p>
<p>Recent focus on Technology and services quality</p> <p>There is an increase in competition in India in the diagnosis segment. To acquire new customers and to retain existing, players need to improve in terms of quality services and report delivery timing.</p>	<ul style="list-style-type: none"> ✓ More than 81% have said that there is an improvement in service quality as compared to previous year – Same day reporting, resolving of customer queries etc. ✓ ~40% of franchisees have mentioned improvement in technology in terms of availability of online reports <i>"With the help of regional labs, PSCs are able to deliver reports to customers within 12 hours" – West India based franchisee owner</i> 	<p>Positive: With plans to set up regional labs in Kolkata and Lucknow, it will help Dr. Lal to improve service quality in those regions.</p>
<p>Addition of new tests in the portfolio</p> <p>Dr. Lal PathLabs is well positioned to gain by adding new tests and services.</p>	<ul style="list-style-type: none"> ✓ <i>Dr. Lal Pathlabs has launched multiple tests in the last one year – cancer, new born baby screening tests, liver and kidney transplant detection tests, molecular, microbiology, RNA DNA test, Vitamin D ultrasensitive etc.</i> <i>"Dr. Lal Pathlabs has 230 marker tests on cancer detection" – Doctor based in Southern region</i> 	<p>Positive: This will help Dr. Lal PathLabs to grow</p>

Kahaani Zameen Par | Second Edition | Dr. Lal PathLabs Ltd.

On ground diagnosis

6th November 2017

BSE Code - 539524 | Scrip Name - LALPATHLAB | CMP - INR 826 | Market Capitalization ~6,883 crores



<p>Dominant market position in North India.</p> <p>Dr. Lal PathLabs is 60 years old brand in organised diagnosis industry and it is highly recommended by doctors in North India.</p>	<ul style="list-style-type: none"> ✓ All the franchisee owners (100%) have chosen Dr. Lal PathLabs in North India over other brands because of brand equity and brand loyalty ✓ As a result of strong brand recall, franchisee owners incur no lead costs for Dr. Lal PathLabs in North India <p><i>"Patients and doctors blindly trust Dr. Lal Pathlabs for report accuracy". – Delhi based franchisee owner</i></p> <ul style="list-style-type: none"> ✓ However few franchisee owners have given feedback that because of internal competition they are under pressure to give discounts to customers 	<p>Positive: This will help the growth of Dr. Lal PathLabs.</p> <p>Cannibalization has started in Northern region. The management should take note of it.</p>
<p>Comparison - East vs. South vs. West</p>	<ul style="list-style-type: none"> ✓ Franchisee owners in East and South are satisfied with Dr. Lal. However in East, 45% of franchisees are not seeing growth in samples. In South, franchisee owners are seeing growth in samples but are facing issues of brand awareness ✓ Western region is a concern for Dr. Lal Pathlabs especially Maharashtra and Gujarat wherein franchisees are shutting shops because of losses and lack of brand awareness <p><i>"In western region we are not getting any support from company. Not even reaching break-even so planning to close down the franchise - Franchisee owner, Mumbai</i></p>	<p>Positive: Setting up of Kolkata reference lab could help in the growth of Dr. Lal</p> <p>Negative: This can hurt the business going forward. Management should immediately look at taking corrective steps.</p>
<p>Growth in Patient Service Centres (PSCs)</p>	<ul style="list-style-type: none"> ✓ Franchise owners are satisfied with Dr. Lal PathLabs in all regions except West. ✓ Most of the franchisee owners (70%) are happy with the support from Dr. Lal Pathlabs for marketing, sales etc. except West ✓ Also satisfaction is high as there are no targets or penalties in Dr. Lal as is the case with Thyrocare 	<p>Positive: This will help in the growth of Dr. Lal</p>
<p>Share of Packages</p>	<ul style="list-style-type: none"> ✓ Share of Packages in samples collected is very low in Dr. Lal PathLabs with around 15% ✓ Promoting/ selling packages is not the focus of franchisee owners as the share of franchisee owner is less in packages vs. individual tests. As a result they do not inform/ recommend packages to customers 	<p>Negative: Management needs to work on the sharing with franchisees if they plan to increase the share of packages</p>

Business Economics

Patient Service Centres (PSC)					
Region	No. of samples Collected daily (Avg)	Revenue (Avg) Rs. in Lakhs per month	Profit % (Avg)	Satisfaction Level	Share of Packages in Total Samples - (Avg)
Overall	19	3.3	27%	Satisfied - 35% Moderately Satisfied - 47% Not Satisfied - 18%	20%
North	22	4.9	21%	Satisfied - 47% Moderately Satisfied - 37% Not Satisfied - 16%	15%
East	16	3.7	24%	Satisfied - 58% Moderately Satisfied - 33% Not Satisfied - 8%	17%
South	23	2.1	34%	Moderately Satisfied - 89% Not Satisfied - 11%	28%
West	16	2.6	28%	Satisfied - 18% Moderately Satisfied - 45% Not Satisfied - 36%	19%

Other Qualitative findings

- ✓ Overall revenue sharing between franchisee and Dr. Lal PathLabs is 67% for routine tests and 76% for test packages respectively
- ✓ A typical franchisee earns a profit of Rs. 50,000-60,000 per month (20-40%) on an average with a focus to generate and collect samples of advanced tests
- ✓ Franchisee agreement/contract is signed for 5 years, at the time of renewal there is no extra charge. The revenue share with Dr. Lal PathLabs is negotiable.
- ✓ The franchisee owners who have been in this business for more than 10 years are satisfied with Dr. Lal pathlabs franchisee as they tend to have relaxed franchisee terms and conditions as compared to other labs
- ✓ In case of Pick-up point (PUP) mode, they can take up franchisee of other brands at the same time. These are mainly doctors. All sample collection materials including courier charges to send test samples to regional labs are incurred by the company

Disclaimer

This report is published for information only. We hereby certify that the views and opinions expressed and presented in this report reflect our own personal views about the firms and companies. Reevolv Advisory Services Private Limited or any of its affiliates, group companies, directors, employees, agents or representatives shall not be liable for any loss or damages whether direct or indirect that may arise from or in connection with the use of the information in this document. This document is the sole property of Reevolv Advisory Services Private Limited and prior permission is required for full or part reproduction. This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose.

This material is subject to change without notice. This document is for information and illustrative purposes only. It is not, and should not be regarded as "investment advice" or as a "recommendation" regarding a course of action, including without limitation as those terms are used in any applicable law or regulation. This information is provided with the understanding that with respect to the material provided herein (i) Reevolv is not acting in a fiduciary or advisory capacity under any contract with you, or any applicable law or regulation, (ii) that you will make your own independent decision with respect to any course of action in connection herewith, as to whether such course of action is appropriate or proper

based on your own judgment and your specific circumstances and objectives, (iii) that you are capable of understanding and assessing the merits of a course of action and evaluating investment risks independently.

The Policy of Reevolv Advisory Services Private Limited is to provide and publish reports which are not partial or misleading, and are clear, fair and independent. We may not receive any compensation from the companies we cover in our reports. The information disclosed in this report is only for the purpose of knowledge and it does not constitute any representation, suggestion, warranty or recommendation. Absence of a discloseable position should not be taken as endorsement on the validity or quality of the research report or recommendation.

The research conducted in this report is made independently and is not controlled or supervised by any other authority. We also clarify that we do not take responsibility or liability for any dispute or conflict of interest arising out of any subject in matter of the report. You should consult your advisors with respect to these areas and the material presented herein. You may not rely on the material contained herein. Reevolv shall not have any liability for any damages of any kind whatsoever relating to this material. No part of this document may be reproduced in any manner, in whole or in part, without the written permission of RASP except for your internal use.

Unless it is specified in the report, Reevolv Advisory Services Private Limited did not receive any income of any kind, and did not manage a public offering for the companies, and it does not expect to receive any kind of compensation. Reevolv Advisory Services Private Limited's Research personnel and research analysts do not compromise the integrity and independence of RASP's research.

Neither researchers nor any person associated with them may have a financial interest in, or an interest to be an officer, advisory board member or a director of the company covered in this report unless disclosed herein.

Disclosure of interest

Analyst Ownership of the stock - Yes

We also confirm that he/she/they have/has not been placed under any pressure, undue influence or intervention by in person/s in making this report. We certify that no nonpublic information or material intellect regarding the subject company has been used while drafting this report. No portion, parts, sections, segments or figures shall be used in similar or/and different manner or way or form.

The data, suggestions and opinion herein are not intended, or directed for distribution to or use by, any entity or individual residing or having office at/in any jurisdiction where doing so would be contrary to law or regulation or which would subject Reevolv Advisory Services Private Limited to any additional registration or licensing requirement within such jurisdiction.

The data and information collected and presented in this report are obtained and collected from the sources we believe to be credible and reliable. We do not verify or warranty as to the correctness or completeness of the data and information presented in this report. Any suggestions or opinion herein reflects the judgment of the Reevolv Advisory Services Private Limited at the date of this publication and they are subject to change at any time without any notification.

To the extent permitted by the laws and regulations, Reevolv Advisory Services Private Limited is not liable whatsoever for any type of loss arising from the use of this report or its contents. Reevolv Advisory Services Private Limited is not responsible for any errors or omissions or for the results obtained from the use of such information and it especially states that it has no financial liability whatsoever to any user on account of the use of information provided in this report. Please verify the veracity of all information on your own before undertaking any alliance. Reevolv Advisory Services Private Limited is not a qualified financial advisor and you should not construe any information discussed herein this report to constitute investment advice. The contents of this report are informational in nature. Information contained herein does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual investors. Before acting on any recommendation, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice.

We encourage all investors to use the information in this report as a resource only to further their own research on all featured companies, stocks, mutual funds, sectors, markets and information presented in this report. Nothing published in this report should be considered as an investment advice or suggestions.

Neither Reevolv Advisory Services Private Limited nor its principals, agents, associates or employees, are licensed to provide investment advice.No materials in this report should be taken as investment advice directly, indirectly, implicitly, or in any manner whatsoever, including but not limited to trading of stocks or investing in mutual funds on a short term or long term basis, or trading of any financial instruments whatsoever. Past or current Performance Is Not Indicative of Future Returns. The information provided in this report is NOT a recommendation or solicitation to buy or sell any securities or mutual funds.

Contact No. +91 86555 05521, +91 - 22 - 2422 0141 or email at research@reevolv.in

CIN: U74140MH2011PTC215709Corporate Address: No. 51, Kalyandas Udyog Bhawan, Sadanand Hasu Tandel Marg, Century Bazaar, Prabhadevi, Mumbai - 400025